Analgesic

• 1. Introduction

  ›

  Analgesics are among the most widely used drugs in human medicine, yet most people reach for them without thinking twice. The word itself comes from Greek roots meaning "without pain" - an- and algos - and the drugs they describe were known as "anodynes" before the 20th century. Today, from a bottle of ibuprofen pulled from a kitchen cabinet to a carefully monitored morphine drip in a hospital ward, analgesics span a vast range of chemical classes, mechanisms, and risks.

  But beneath that everyday familiarity lie questions that are far from simple. Why do some pain relievers work on a headache but fail against nerve damage? How did a class of drugs designed to be safer than aspirin end up pulling its leading product from the market after it raised cardiovascular risk by 40%? What happens when the drug meant to dull pain actually makes it worse? And what separates a common over-the-counter tablet from a substance that requires a prescription and medical supervision?

  The story of analgesics is one of competing mechanisms, unexpected trade-offs, and a medical field still working out exactly how pain itself operates.

• 2. A Drug for Every Pain Type

  ›

  Paracetamol - also known as acetaminophen or APAP - sits at the mild end of the analgesic spectrum. Classified as a mild analgesic, it treats mild to moderate pain and is generally regarded as safe at recommended doses. Combined with opioid pain medication, it can be used for more severe pain, including cancer pain and post-surgical recovery. It can be taken by mouth, rectally, or administered intravenously, and its effects last between two and four hours.

  Nonsteroidal anti-inflammatory drugs, almost always abbreviated to NSAIDs, cover a broader range of conditions. They decrease pain, lower fever, and at higher doses reduce inflammation. Aspirin, ibuprofen, naproxen, and diclofenac - the most prominent members of this group - are all available over the counter in most countries. That accessibility reflects how well-tolerated they generally are at standard doses, though the comparison table of NSAIDs in clinical reference materials reveals dozens of distinct agents with varying half-lives, routes of administration, and risk profiles.

  For neuropathic pain - pain originating from nerve damage rather than tissue injury - neither paracetamol nor standard NSAIDs are the first line of reasoning. Recent research has pointed toward two drug classes not normally thought of as analgesics at all: tricyclic antidepressants, such as amitriptyline, and anticonvulsants, such as gabapentin and pregabalin. These drugs were developed for entirely different purposes yet ended up finding a place in pain management through the same pathway they use elsewhere - dampening abnormal electrical signaling in the nervous system.

• 3. The COX Enzyme Twist

  ›

  The cyclooxygenase enzyme that NSAIDs inhibit was eventually found to have at least two distinct versions: COX-1 and COX-2. Research suggested that most of the harmful side effects of NSAIDs - particularly gastrointestinal hemorrhage - were driven by blocking COX-1, while the pain-relieving effects came mainly from blocking COX-2. That finding opened a new design opportunity.

  COX-2 inhibitors such as rofecoxib, celecoxib, and etoricoxib were developed specifically to target the COX-2 enzyme while leaving COX-1 largely untouched. They were equally effective analgesics compared with traditional NSAIDs and caused less gastrointestinal hemorrhage in particular. For patients who had struggled with stomach bleeding from standard NSAIDs, they seemed like a meaningful improvement.

  Then, after widespread adoption, the picture changed. Most drugs in this class were found to increase the risk of cardiovascular events by 40% on average. Rofecoxib and valdecoxib were withdrawn from the market. Other COX-2 inhibitors received warnings. The exception among them appears to be etoricoxib, whose risk of thrombotic events is described as similar to that of the non-COX-2 NSAID diclofenac - itself already noted as more prone to myocardial infarction, stroke, and hypertension than most of its NSAID siblings. The COX-2 story is a clear illustration of how targeting one problem in a biological system can open another.

• 4. Opioids and the Tolerance Problem

  ›

  Morphine is the archetypal opioid. It and other opioids - codeine, oxycodone, hydrocodone, dihydromorphine, pethidine - all act on the cerebral opioid receptor system in similar ways. Most are classified as mu opioid receptor agonists, binding directly to receptors that modulate how the brain and spinal cord process pain signals.

  Tramadol and tapentadol occupy a different position in the opioid family. Tramadol is structurally closer to venlafaxine than to codeine. It delivers analgesia through mild agonism of the mu receptor but also acts as a weak serotonin releasing agent and norepinephrine reuptake inhibitor. Tapentadol shares some structural similarities with tramadol and is believed to work through two and possibly three distinct modes of action simultaneously.

  Opioids are very effective analgesics, but the range of side effects is broad. Constipation occurs in almost all patients on opioids, and laxatives are typically co-prescribed. Nausea and vomiting are common when patients start morphine. Pruritus - itching - may require switching to a different opioid entirely. At higher doses, opioid toxicity can produce confusion, respiratory depression, myoclonic jerks, and pinpoint pupils.

  Tolerance compounds these management challenges. Frequent use can lead to diminished effect, sometimes requiring higher doses to maintain the same level of pain control. One clinical response is opioid rotation therapy, in which a patient is routinely switched between two or more non-cross-tolerant opioid medications to prevent exceeding safe dosages. Opioid tolerance must also be distinguished from opioid-induced hyperalgesia, which is a separate phenomenon: rather than needing more drug to get the same relief, the patient's exposure to opioids has actually increased their sensitivity to pain, and can even make non-painful stimuli feel painful - a condition called allodynia.

• 5. The Adjuvant Category

  ›

  A substantial range of drugs that were introduced for other purposes have found lasting roles in pain management. These are called adjuvant analgesics or atypical analgesics, and they include drugs with anticonvulsant, anticholinergic, and antispasmodic properties, as well as other drugs with central nervous system actions.

  Dextromethorphan has been noted to slow the development of and reverse tolerance to opioids, as well as to provide additional analgesia by acting on NMDA receptors. Ketamine shares that NMDA mechanism. Some opioids, including methadone and ketobemidone and perhaps piritramide, have intrinsic NMDA-blocking activity built into their structure.

  The anticonvulsant carbamazepine is used to treat neuropathic pain. Gabapentinoids - gabapentin and pregabalin - are prescribed for neuropathic pain and work by blocking the alpha-2-delta subunit of voltage-gated calcium channels, though they tend to have additional mechanisms of action as well. Orphenadrine, mexiletine, cyclobenzaprine, and hyoscine are among the named adjuvant analgesics with antispasmodic or anticholinergic properties used alongside opioids, particularly when the pain has a neuropathic origin.

  Some adjuvants work by directly potentiating the effect of a given opioid dose rather than adding their own analgesic effect. Hydroxyzine, promethazine, carisoprodol, and tripelennamine are all noted in the clinical literature as agents that can increase the pain-killing ability of an opioid without being analgesics themselves.

• 6. Alcohol, Cannabis, and the Edges

  ›

  Alcohol has biological, mental, and social effects that all influence how it interacts with pain. Moderate use can lessen certain types of pain in certain circumstances. The majority of its analgesic effects come from antagonizing NMDA receptors - the same pathway used by ketamine - which decreases the activity of glutamate, the primary excitatory neurotransmitter. Alcohol also functions as an analgesic to a lesser degree by increasing the activity of GABA, the primary inhibitory neurotransmitter. Using alcohol to treat pain has also been observed to lead to negative outcomes, including excessive drinking and alcohol use disorder.

  Medical cannabis refers to cannabis or its cannabinoids used to treat disease or improve symptoms. There is evidence that cannabis can be used to treat chronic pain and muscle spasms, with some trials indicating improved relief of neuropathic pain over opioids. The comparison with opioids in neuropathic pain is notable given how established opioids are as the standard of care for severe pain in other contexts.

  At the more specialized end of the spectrum sits ziconotide, a blocker of N-type voltage-gated calcium channels. It is administered intrathecally - directly into the fluid surrounding the spinal cord - for the relief of severe pain, usually cancer-related. Flupirtine, used in Europe for moderate to strong pain as well as migraine and muscle spasm, has no significant anticholinergic properties and is believed to have no activity on dopamine, serotonin, or histamine receptors; it is not considered addictive. Among the investigational compounds, researchers have been looking at subtype-selective voltage-gated sodium channel blockers including funapide and raxatrigine, and multimodal agents such as ralfinamide.

• 7. Combinations and Caution

  ›

  Analgesics are frequently combined, and paracetamol-codeine preparations appear in many non-prescription pain relievers as a familiar example. The rationale is pharmacological: hitting pain at multiple sites of action through different mechanisms can be more effective than any single drug alone. The combination of paracetamol, aspirin, ibuprofen, naproxen, and other NSAIDs with weak to mid-range opiates up to about the hydrocodone level has been described as showing beneficial synergistic effects in that way.

  The evidence on combination analgesic products is less straightforward than that rationale suggests. Several combination products have been shown to have few efficacy benefits when compared to similar doses of their individual components. The risk profile also changes when drugs are combined: these combinations can result in significant adverse events, including accidental overdoses, most often due to confusion arising from the multiple and often non-independently-acting components.

  Topical preparations represent a different approach to managing that trade-off. Topical NSAIDs provide pain relief in common conditions such as muscle sprains and overuse injuries, and because systemic side effects are lesser with topical application, they may be preferred over oral medications. Ibuprofen- or diclofenac-containing gels are among the named options. Lidocaine, which is technically an anesthetic rather than an analgesic, is used for painful mouth sores and to numb areas for dental work and minor procedures. In February 2007, the FDA notified consumers and healthcare professionals about the potential hazards of topical anesthetics - including lidocaine, tetracaine, benzocaine, and prilocaine - entering the bloodstream when applied in large doses to the skin without medical supervision.